Format
Items per page
Sort by

Send to:

Choose Destination

Results: 18

References for PMC Articles for PubMed (Select 22876107)

1.

Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?

Schneider JP, Matthews M, Jamison RN.

CNS Drugs. 2010 Oct;24(10):805-10. doi: 10.2165/11584260-000000000-00000. Review.

PMID:
20839893
2.

Opioid formulations designed to resist/deter abuse.

Raffa RB, Pergolizzi JV Jr.

Drugs. 2010 Sep 10;70(13):1657-75. doi: 10.2165/11537940-000000000-00000. Review.

PMID:
20731474
3.

Morphine/naltrexone.

Duggan ST, Scott LJ.

CNS Drugs. 2010 Jun;24(6):527-38. doi: 10.2165/11204620-000000000-00000. Review.

PMID:
20443648
4.

OROS hydromorphone prolonged release: a review of its use in the management of chronic, moderate to severe pain.

Carter NJ, Keating GM.

CNS Drugs. 2010 Apr;24(4):337-61. doi: 10.2165/11202580-000000000-00000. Review.

PMID:
20297858
5.

Long-acting opioids and short-acting opioids: appropriate use in chronic pain management.

Fine PG, Mahajan G, McPherson ML.

Pain Med. 2009 Jul;10 Suppl 2:S79-88. doi: 10.1111/j.1526-4637.2009.00666.x. Review.

PMID:
19691687
6.

Multimodal analgesia for chronic pain: rationale and future directions.

Argoff CE, Albrecht P, Irving G, Rice F.

Pain Med. 2009 Jul;10 Suppl 2:S53-66. doi: 10.1111/j.1526-4637.2009.00669.x. Review.

PMID:
19691685
7.

Update on abuse-resistant and abuse-deterrent approaches to opioid formulations.

Webster L.

Pain Med. 2009 Jul;10 Suppl 2:S124-33. doi: 10.1111/j.1526-4637.2009.00672.x. Review.

PMID:
19691683
8.

Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.

Orman JS, Keating GM.

Drugs. 2009;69(5):577-607. doi: 10.2165/00003495-200969050-00006. Review.

PMID:
19368419
9.

Opioid formulations in development designed to curtail abuse: who is the target?

Webster LR, Bath B, Medve RA.

Expert Opin Investig Drugs. 2009 Mar;18(3):255-63. doi: 10.1517/13543780902751622 . Review.

PMID:
19243277
10.

Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.

Largent-Milnes TM, Guo W, Wang HY, Burns LH, Vanderah TW.

J Pain. 2008 Aug;9(8):700-13. doi: 10.1016/j.jpain.2008.03.005. Epub 2008 May 12.

PMID:
18468954
11.

Abuse-deterrent opioid formulations: are they a pipe dream?

Katz N.

Curr Rheumatol Rep. 2008 Jan;10(1):11-8. Review.

PMID:
18457606
12.

Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification.

Helm S, Trescot AM, Colson J, Sehgal N, Silverman S.

Pain Physician. 2008 Mar-Apr;11(2):225-35. Review.

13.

Challenges in the development of prescription opioid abuse-deterrent formulations.

Katz NP, Adams EH, Chilcoat H, Colucci RD, Comer SD, Goliber P, Grudzinskas C, Jasinski D, Lande SD, Passik SD, Schnoll SH, Sellers E, Travers D, Weiss R.

Clin J Pain. 2007 Oct;23(8):648-60. Review.

PMID:
17885342
14.

Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation.

Webster LR.

Expert Opin Investig Drugs. 2007 Aug;16(8):1277-83. Review.

PMID:
17685875
15.
16.

Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain.

Webster LR, Butera PG, Moran LV, Wu N, Burns LH, Friedmann N.

J Pain. 2006 Dec;7(12):937-46.

PMID:
17157780
17.

Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse.

Passik SD, Kirsh KL, Donaghy KB, Portenoy RK.

Clin J Pain. 2006 Feb;22(2):173-81.

PMID:
16428952
18.

Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain.

Palangio M, Northfelt DW, Portenoy RK, Brookoff D, Doyle RT Jr, Dornseif BE, Damask MC.

J Pain Symptom Manage. 2002 May;23(5):355-68.

PMID:
12007754
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk